- $677.97m
- $625.73m
- $73.24m
- 99
- 16
- 86
- 75
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 29.07 | ||
| PEG Ratio (f) | 2.12 | ||
| EPS Growth (f) | 15.89% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.81 | ||
| Price to Tang. Book | 8.1 | ||
| Price to Free Cashflow | 40.34 | ||
| Price to Sales | 9.26 | ||
| EV to EBITDA | 27.47 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 24.46% | ||
| Return on Equity | 24.31% | ||
| Operating Margin | 29.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 31.72 | 41.81 | 53.3 | 65.56 | 73.24 | 79.41 | 93.49 | 13.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -94.17 | +1519.26 | +37.07 | +33.18 | +11.29 | +16.29 | +15.14 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gausses.
Directors
- Roger Susi CHM (67)
- Chris Scott CFO (51)
- Monty Allen IND (68)
- James Hawkins IND (65)
- Anthony Vuoto IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 8th, 2014
- Public Since
- July 16th, 2014
- No. of Shareholders
- 3
- No. of Employees
- 160
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 12,715,072
- Address
- 1025 Willa Springs Dr., WINTER SPRINGS, 32708
- Web
- https://www.iradimed.com/
- Phone
- +1 4076778022
- Auditors
- RSM US LLP
Upcoming Events for IRMD
IRadimed Corp Annual Shareholders Meeting
Q2 2025 IRadimed Corp Earnings Release
Similar to IRMD
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
What is the Iradimed share price?
As of Today at 21:23 UTC, shares in Iradimed are trading at $53.32. This share price information is delayed by 15 minutes.
How has the Iradimed share price performed this year?
Shares in Iradimed last closed at $53.32 and the price had moved by +28.57% over the past 365 days. In terms of relative price strength the Iradimed share price has outperformed the S&P500 Index by +18.68% over the past year.
What are the analyst and broker recommendations for Iradimed?
The overall consensus recommendation for Iradimed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Iradimed dividend yield?
The Iradimed dividend yield is 1.13% based on the trailing twelve month period.
Does Iradimed pay a dividend?
Last year, Iradimed paid a total dividend of $0.60, and it currently has a trailing dividend yield of 1.13%. We do not have any data on when Iradimed is to next pay dividends.
When does Iradimed next pay dividends?
We do not have data on when Iradimed is to next pay dividends. The historic dividend yield on Iradimed shares is currently 1.13%.
How do I buy Iradimed shares?
To buy shares in Iradimed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Iradimed?
As of the previous close price of $53.32, shares in Iradimed had a market capitalisation of $677.97m.
Where are Iradimed shares listed?
Here are the trading details for Iradimed:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: IRMD
What kind of share is Iradimed?
Based on an overall assessment of its quality, value and momentum Iradimed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Iradimed share price forecast for 2025?
The analyst consensus target price for shares in Iradimed is $71.00. That is 33.16% above the last closing price of $53.32.
Analysts covering Iradimed currently have a consensus Earnings Per Share (EPS) forecast of $1.75 for the next financial year.
Find out moreWhat is the trend in the Iradimed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Iradimed. Over the past six months, its share price has outperformed the S&P500 Index by +11.53%.
As of the last closing price of $53.32, shares in Iradimed were trading +2.93% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Iradimed PE Ratio?
The Iradimed PE ratio based on its reported earnings over the past 12 months is 29.07. The shares last closed at $53.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Iradimed?
Iradimed's management team is headed by:
- Roger Susi - CHM
- Chris Scott - CFO
- Monty Allen - IND
- James Hawkins - IND
- Anthony Vuoto - IND